<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062816</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 14803-CS3</org_study_id>
    <nct_id>NCT00062816</nct_id>
  </id_info>
  <brief_title>Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral&#xD;
      activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to&#xD;
      patients who either failed to have at least a 100-fold HCV reduction at Week 12 of standard&#xD;
      therapy or still have detectable HCV at Week 24.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previously untreated chronic hepatitis C patients undergoing therapy with peginterferon alfa&#xD;
      and ribavirin have a very poor probability of achieving a sustained virologic response if&#xD;
      they either do not have a 100-fold or greater reduction in their plasma HCV RNA levels at the&#xD;
      12th week of treatment or have detectable plasma HCV RNA at the 24th week of treatment. ISIS&#xD;
      14803 is an experimental antiviral medication for the treatment of chronic hepatitis C that&#xD;
      has been given to chronic hepatitis C patients in two previous single-agent clinical trials&#xD;
      (approximately 70 patients).&#xD;
&#xD;
      In this clinical research study, 12 weeks of ISIS 14803 treatment will be added to the&#xD;
      peginterferon alfa and ribavirin treatment regimen of previously untreated chronic hepatitis&#xD;
      C patients who have a very poor probability of achieving a sustained virologic response based&#xD;
      upon either of the above two criteria. Enrolled patients must continue to be treated with&#xD;
      peginterferon alfa and ribavirin and must begin ISIS 14803 treatment within four weeks of&#xD;
      their HCV RNA result report date. ISIS 14803 will be given as a two-hour intravenous&#xD;
      infusion, two times each week, for 12 weeks. Depending on their HCV response to the&#xD;
      three-drug combination, patients may continue treatment with peginterferon alfa and ribavirin&#xD;
      after the end of ISIS 14803 treatment. Patients will be monitored for at least eight weeks&#xD;
      (for safety) after the end of ISIS 14803 treatment and possibly for longer (for sustained&#xD;
      virologic response). Two dose levels of ISIS 14803 will be studied in this trial, 3 and 6&#xD;
      mg/kg ideal body weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>22</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 14803, peginterferon alfa, ribavirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (partial list):&#xD;
&#xD;
          -  Age 18 to 65 years.&#xD;
&#xD;
          -  Infection with HCV.&#xD;
&#xD;
          -  Prior liver biopsy indicating chronic hepatitis.&#xD;
&#xD;
          -  Received at least 12 weeks of continuous peginterferon alfa and ribavirin therapy.&#xD;
&#xD;
          -  HCV infection was untreated prior to current peginterferon alfa and ribavirin regimen.&#xD;
&#xD;
          -  Either less than 100-fold reduction in plasma or serum HCV RNA despite receiving 12&#xD;
             weeks of peginterferon alfa and ribavirin therapy or detectable HCV RNA at week 24 of&#xD;
             therapy.&#xD;
&#xD;
          -  Prothrombin time and aPTT within normal reference range.&#xD;
&#xD;
          -  Serum bilirubin concentration within normal reference range.&#xD;
&#xD;
          -  Give written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion criteria (partial list):&#xD;
&#xD;
          -  Pregnant women or nursing mothers or women of childbearing potential without adequate&#xD;
             contraception.&#xD;
&#xD;
          -  Systemic corticosteroid therapy within 3 months of screening.&#xD;
&#xD;
          -  Serum ALT greater than 5 x upper limit of normal range.&#xD;
&#xD;
          -  HIV or HBV infection.&#xD;
&#xD;
          -  Decompensated liver disease.&#xD;
&#xD;
          -  Evidence of cirrhosis.&#xD;
&#xD;
          -  Severe depression with suicidal ideation requiring hospitalization within one year of&#xD;
             screening.&#xD;
&#xD;
          -  Any disease condition associated with active bleeding or requiring anticoagulation&#xD;
             with heparin or warfarin.&#xD;
&#xD;
          -  Any condition which, in the opinion of the Investigator, would preclude participation&#xD;
             in or interfere with compliance.&#xD;
&#xD;
          -  Alcohol or drug abuse.&#xD;
&#xD;
          -  Is undergoing or has undergone treatment with another investigational drug, biologic&#xD;
             agent or device within 30 days of screening&#xD;
&#xD;
          -  History of cryoglobulinemia or vasculitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Birmingham Gastroenterology Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Trials</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western States Clinical Research, Inc.</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Gastroenterology Assoc.</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMG Healthcare, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureCare Studies</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Institute for Digestive Diseases and Sciences, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blair Gastroenterology Associates</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Center of the MidSouth, P.C.</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastroenterology Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine-VAMC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire VAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Gastroenterolgy Assoc.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Digestive Disease Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>June 16, 2003</study_first_submitted>
  <study_first_submitted_qc>June 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2003</study_first_posted>
  <last_update_submitted>October 15, 2007</last_update_submitted>
  <last_update_submitted_qc>October 15, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2007</last_update_posted>
  <keyword>Hepatitis</keyword>
  <keyword>Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

